vimarsana.com

Latest Breaking News On - Hangzhou sciwind biosciences co - Page 1 : vimarsana.com

Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference

/PRNewswire/ Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat.

United statesNew zealandSan diegoAmerican diabetes associationPrnewswire sciwind biosciences co ltdBreaking poster presentationActive controlled phaseGlycemic controlWeight lossHangzhou sciwind biosciences co

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China

/PRNewswire/ Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat.

Thai panPrnewswire sciwind biosciences co ltdNational medical products administrationHangzhou sciwind biosciences co

Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity

/PRNewswire/ Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic.

New zealandMohammed junaidiPrnewswire sciwind biosciencesSciwind biosciencesThai panClinical research at sciwindVice presidentClinical researchHangzhou sciwind biosciences co

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes

/PRNewswire/ Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat.

Martijn fenauxNonclinical development translational science at sciwindPrnewswire sciwind biosciences co ltdNonclinical developmentTranslational scienceHangzhou sciwind biosciences co

Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics

/PRNewswire/ Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic.

Weidong zhongWayne jiangSciwind biosciencesHangzhou sciwind biosciences co

vimarsana © 2020. All Rights Reserved.